Although ibrutinib or zanubrutinib administration has a potential HBVr complication, there was no episode of HBV-hepatitis with a prophylactic NAT, and HBV infection might not affect response rates or survival among R/R DLBCL patients post BTKis treatment. Here, BRD2 is linked to diffuse large B-cell lymphoma.